Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty
349-F4-050
Product Details
Citations (15)
FAQs
Supplemental Products
Reviews

Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF Summary

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGFR3/Flt‑4 Fc Chimera at 5 μg/mL (100 μL/well) binds Recombinant Human VEGF-D (Catalog # 622-VD) with an apparent Kd <15 nM.
Source
Mouse myeloma cell line, NS0-derived human VEGFR3/Flt-4 protein
Human Flt-4
(Tyr25-Ile776) &
(Ser473-Ile776)
Accession # P35916
IEGRDMD Human IgG1
(Pro100-Lys330)
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Tyr25 & Ser473
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
112 kDa (monomer)
SDS-PAGE
145-150 kDa, 90-95 kDa and 75-80 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

349-F4

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 200 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGFR3/Flt-4

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt‑1) and VEGFR3 (Flt‑4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt‑4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.

References
  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Long Name
Vascular Endothelial Growth Factor Receptor 3
Entrez Gene IDs
2324 (Human); 14257 (Mouse)
Alternate Names
EC 2.7.10; EC 2.7.10.1; FLT4; Flt-4; fms-related tyrosine kinase 4; LMPH1A; PCLFLT41; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; Tyrosine-protein kinase receptor FLT4; vascular endothelial growth factor receptor 3; VEGF R3; VEGFR3; VEGFR-3; VEGFR3Fms-like tyrosine kinase 4

Citations for Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

15 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth
    Authors: J Zhang, H Li, Q Wu, Y Chen, Y Deng, Z Yang, L Zhang, B Liu
    Redox Biol, 2019;22(0):101116.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Neutralization
  2. Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics
    Authors: SB Mamer, S Chen, JC Weddell, A Palasz, A Wittenkell, M Kumar, PI Imoukhuede
    Sci Rep, 2017;7(1):16439.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance
  3. Differential receptor binding and regulatory mechanisms for the lymphangiogenic growth factors VEGF-C and VEGF-D
    Authors: Marc G Achen
    J. Biol. Chem., 2016;0(0):.
    Applications: Bioassay
  4. Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
    Authors: Terrance G Johns
    Sarcoma, 2016;2016(0):3484673.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis.
    Authors: Kyu-Yeon Han, Jin-Hong Chang, Hyun Lee, Dimitri T Azar
    Investigative Ophthalmology & Visual Science, 2016;0(0):1552-5783.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Enzyme Assay
  6. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
    Authors: Harris, Nicole C, Davydova, Natalia, Roufail, Sally, Paquet-Fifield, Sophie, Paavonen, Karri, Karnezis, Tara, Zhang, You-Fang, Sato, Teruhiko, Rothacker, Julie, Nice, Edouard, Stacker, Steven A, Achen, Marc G
    J Biol Chem, 2013;288(12):8176-86.
    Species: Human
    Sample Types: Protein
    Applications: Enzyme Assay
  7. Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model.
    Authors: Tabata T, Petitt M, Fang-Hoover J, Rivera J, Nozawa N, Shiboski S, Inoue N, Pereira L
    Am J Pathol, 2012;181(5):1540-59.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
    Authors: Mouawad R, Spano JP, Comperat E, Capron F, Khayat D
    Eur. J. Cancer, 2009;45(8):1407-14.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA Developmet
  9. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
    Authors: Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML
    Carcinogenesis, 2009;30(12):2005-13.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.
    Authors: Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, Olsen BR, Alitalo K
    Nat. Cell Biol., 2008;10(5):527-37.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.
    Authors: Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K
    J. Exp. Med., 2007;204(6):1431-40.
    Species: Porcine
    Sample Types: Whole Cells
    Applications: Bioassay
  12. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain.
    Authors: Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Breant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL
    Nat. Neurosci., 2006;9(3):340-8.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation.
    Authors: Red-Horse K, Rivera J, Schanz A, Zhou Y, Winn V, Kapidzic M, Maltepe E, Okazaki K, Kochman R, Vo KC, Giudice L, Erlebacher A, McCune JM, Stoddart CA, Fisher SJ
    J. Clin. Invest., 2006;116(10):2643-52.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.
    Authors: Lin J, Lalani AS, Harding TC
    Cancer Res., 2005;65(15):6901-9.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  15. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
    Authors: Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS
    Int. J. Cancer, 2003;104(5):603-10.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Recombinant Proteins

Reconstitution Buffers

Reviews for Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF and earn rewards!

Have you used Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review